Keywords: AstraZeneca, Zibotentan, Prostate cancer, Phase III failure

Further cancer pipeline disappointment for AstraZeneca as zibotentan fails in Ph III

Article | 07 February 2011

Print This

In yet a further setback for its cancer drug pipeline, Anglo-Swedish drug major, AstraZeneca (LSE: AZN) today announced that the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in